Other headlines:Miller joins fMRI companyYankees take Philips ‘out to the ballpark’
A new facility for making GE digital mammography detectors opened June 5 near the Global Research center that pioneered the flat panel. The sprawling plant, covering 230,000 square feet, cost $165 million to construct at the Rensselaer Technology Park in North Greenbush, NY. The new facility will fabricate the detectors now integrated into GE's Senographe digital mammography system, as well as ones for the company's next-generation breast tomosynthesis systems, which will acquire volumetric data about the breast. More than 95% of the flat-panel detectors manufactured by GE since 1999 are still in service, according to GE. About 4000 GE Senographe systems are currently in use worldwide. The first such system was shipped in 2000.
Former Vital Images chief executive Jay D. Miller has taken the reins as president and CEO of Kappametrics, a Chantilly, VA, company specializing in technology that records EEG data in real-time during fMR scans of the brain. Pending FDA marketing clearance, the company's flagship product, fEEG, promises a more detailed mapping of brain activity to improve the understanding and diagnosis of chronic neurological disorders. Kappametrics plans to pitch fEEG initially for academic and clinical research.
The New York Yankees have signed Philips Healthcare. An agreement that makes Philips the ball club's official supplier of medical equipment will bring digital radiography and external defibrillators to Yankee Stadium. The Philips BuckyDiagnost will be installed inside the Yankees' clubhouse. Automated external defibrillators will be available in player areas and in select locations throughout the stadium to provide emergency care to fans, if needed.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.